Table 2.

BH3 Profiling assayed biomarkers and respective significances in response discrimination.

BH3 Peptide	Mean %Priming +/− SD		p-value*	AUC [95%CI]
	NR	CR
BIM	70.1 ± 32.6	88.2 ± 17.6	0.023	0.68 [0.53,0.82]
BIM(0.1)	13.8 ± 13.4	36.8 ± 21.2	0.0000018	0.83 [0.72,0.93]
PUMA	44.7 ± 29.5	64.0 ± 22.7	0.017	0.69 [0.54,0.84]
PUMA(10)	33.3 ± 24.3	50.4 ± 23.7	0.0064	0.71 [0.58,0.85]
NOXA	26.3 ± 15.5	35.1 ± 24.9	0.20	0.60 [0.46,0.75]
BAD	33.2 ± 29.6	52.7 ± 24.3	0.014	0.70 [0.55,0.85]
BMF	45.6 ± 31.6	64.4 ± 24.9	0.016	0.69 [0.53,0.84]
HRK	20.8 ± 22.4	36.6 ± 22.4	0.010	0.72 [0.57,0.88]
PUMA2A	10.8 ± 19.5	16.1 ± 18.9	0.16	0.61 [0.45,0.78]

Summary of the mean % priming (±S.D), p-values and areas under the curve (AUC) for all profiling biomarkers analyzed for non-response (NR) and clinical response (CR) AML patient specimens. BIM(0.1) was identified as a highly significant biomarker (p<0.001 and AUC>0.80) PUMA(10) was also (borderline) statistically significant (p<0.007). Statistical significance was by Mann-Whitney Analysis.